Found: 11
Select item for more details and to access through your institution.
Reorienting the Fab Domains of Trastuzumab Results in Potent HER2 Activators.
- Published in:
- PLoS ONE, 2012, v. 7, n. 12, p. 1, doi. 10.1371/journal.pone.0051817
- By:
- Publication type:
- Article
γ-Heregulin: a novel heregulin isoform that is an autocrine growth factor for the human breast cancer cell line, MDA-MB-175.
- Published in:
- Oncogene, 1997, v. 15, n. 12, p. 1385, doi. 10.1038/sj.onc.1201317
- By:
- Publication type:
- Article
Multiple Family Group Therapy in a Drug and Alcohol Rehabilitation Centre.
- Published in:
- Australian & New Zealand Journal of Family Therapy, 2008, v. 29, n. 1, p. 17, doi. 10.1375/anft.29.1.17
- By:
- Publication type:
- Article
Erratum: Clinical responses to ERK inhibition in BRAF<sup>V600E</sup>-mutant colorectal cancer predicted using a computational model.
- Published in:
- 2017
- By:
- Publication type:
- Correction Notice
Clinical responses to ERK inhibition in BRAF<sup>V600E</sup>-mutant colorectal cancer predicted using a computational model.
- Published in:
- NPJ Systems Biology & Applications, 2017, v. 3, n. 1, p. N.PAG, doi. 10.1038/s41540-017-0016-1
- By:
- Publication type:
- Article
High cell-surface density of HER2 deforms cell membranes.
- Published in:
- Nature Communications, 2016, v. 7, n. 9, p. 12742, doi. 10.1038/ncomms12742
- By:
- Publication type:
- Article
Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2012, v. 69, n. 4, p. 1063, doi. 10.1007/s00280-011-1806-6
- By:
- Publication type:
- Article
Blocking NRG1 and Other Ligand-Mediated Her4 Signaling Enhances the Magnitude and Duration of the Chemotherapeutic Response of Non-Small Cell Lung Cancer.
- Published in:
- Science Translational Medicine, 2013, v. 5, n. 171, p. 1, doi. 10.1126/scitranslmed.3004438
- By:
- Publication type:
- Article
Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti–PD‐L1, for BRCA wild‐type, platinum‐sensitive, recurrent ovarian cancer.
- Published in:
- Cancer (0008543X), 2024, v. 130, n. 11, p. 1940, doi. 10.1002/cncr.35222
- By:
- Publication type:
- Article
Correction: Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors.
- Published in:
- 2018
- By:
- Publication type:
- Correction Notice
Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors.
- Published in:
- PLoS ONE, 2017, v. 12, n. 10, p. 1, doi. 10.1371/journal.pone.0185862
- By:
- Publication type:
- Article